Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Horizon Therapeutics Public Limited Company shares valued at $3,066,323 were sold by Pasternak Andy on Jan 17. At $113.03 per share, Pasternak Andy sold 27,129 shares. The insider’s holdings dropped to 56,338 shares worth approximately $6.24 million following the completion of this transaction.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Also, Cox Aaron sold 36,148 shares, netting a total of over 4,090,847 in proceeds. Following the sale of shares at $113.17 each, the insider now holds 277 shares.
Before that, SHERMAN JEFFREY W had sold 3,368 shares from its account. In a trade valued at $380,921, the EVP and Chief Medical Officer traded Horizon Therapeutics Public Limited Company shares for $113.10 each. Upon closing the transaction, the insider’s holdings decreased to 3,368 shares, worth approximately $4.0 million.
As published in their initiating research note from H.C. Wainwright on November 01, 2022, Horizon Therapeutics Public Limited Company [HZNP] has been a Neutral and the price target has been revised to $74. This represents a -49.59% premium over Thursday’s closing price. Analysts at SVB Leerink downgraded the stock from ‘”an Outperform”‘ to ‘”a Mkt perform”‘ outlook in a report released in early August. As of June 14, 2022, UBS has initiated its “Buy” rating for HZNP.
Analyzing HZNP Stock Performance
On Thursday, Horizon Therapeutics Public Limited Company [NASDAQ: HZNP] plunged -0.05% to $110.70. The stock’s lowest price that day was $110.48, but it reached a high of $111.07 in the same session. During the last five days, there has been a surge of approximately 0.93%. Over the course of the year, Horizon Therapeutics Public Limited Company shares have dropped approximately -2.72%. Shares of the company reached a 52-week high of $113.70 on 01/03/23 and a 52-week low of $108.01 on 01/31/23. A 50-day SMA is recorded $111.85, while a 200-day SMA reached $84.65. Nevertheless, trading volume fell to 1.98 million shares from 2.29 million shares the previous day.
Support And Resistance Levels for Horizon Therapeutics Public Limited Company (HZNP)
According to the 24-hour chart, there is a support level at 110.43, which, if violated, would cause prices to drop to 110.16. In the upper region, resistance lies at 111.02. The next price resistance is at 111.34. RSI (Relative Strength Index) is 57.50 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.62, which suggests the price will decrease in the coming days. Percent R is at 18.32%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
Which companies own the most shares of Horizon Therapeutics Public Limited Company (HZNP)?
According to The Vanguard Group, Inc. filings, the company currently owns 21,309,270 shares, which is about 9.39% of the total HZNP shares outstanding. The investor’s shares have appreciated by 562,439 from its previous 13-F filing of 20746831.0 shares. With the completion of the buy transaction, BlackRock Fund Advisors’s stake is now worth $1,219,497,752. Avoro Capital Advisor LLC acquire a 36.59% interest valued at $768.04 million while HBK Investments LP 0 stake. In its current portfolio, SSgA Funds Management, Inc. holds 5,332,371 shares valued at $585.07 million.
In terms of Horizon Therapeutics Public Limited Company share price expectations, FactSet research, analysts set an average price target of $115.50 in the next 12 months, up nearly 5.18% from the previous closing price of $110.76. Analysts anticipate Horizon Therapeutics Public Limited Company stock to reach $140.00 by 2023, with the lowest price target being $74.00. In spite of this, 10 analysts ranked Horizon Therapeutics Public Limited Company stock as a Hold at the end of 2023. On May 23, 2022, SVB Leerink assigned a price target of “a Mkt perform” to the stock and initiated coverage with a $95.